loading
前日終値:
$107.50
開ける:
$106.46
24時間の取引高:
394.96K
Relative Volume:
0.57
時価総額:
$5.41B
収益:
$338.46M
当期純損益:
$-310.96M
株価収益率:
-16.66
EPS:
-6.53
ネットキャッシュフロー:
$-132.82M
1週間 パフォーマンス:
+5.59%
1か月 パフォーマンス:
-2.84%
6か月 パフォーマンス:
+31.68%
1年 パフォーマンス:
+30.03%
1日の値動き範囲:
Value
$106.46
$110.44
1週間の範囲:
Value
$102.26
$110.44
52週間の値動き範囲:
Value
$72.21
$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name
名前
Axsome Therapeutics Inc
Name
セクター
Healthcare (1163)
Name
電話
(212) 332-3241
Name
住所
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Name
職員
589
Name
Twitter
Name
次回の収益日
2025-02-18
Name
最新のSEC提出書
Name
AXSM's Discussions on Twitter

AXSM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
AXSM
Axsome Therapeutics Inc
108.83 5.41B 338.46M -310.96M -132.82M -6.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.91 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
548.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.69 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
539.40 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
243.63 28.51B 3.81B -644.79M -669.77M -6.24

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-03 開始されました Oppenheimer Outperform
2025-04-07 開始されました Jefferies Buy
2025-02-11 開始されました Deutsche Bank Buy
2024-12-31 繰り返されました Mizuho Outperform
2024-09-03 開始されました Wells Fargo Overweight
2024-08-06 アップグレード BofA Securities Neutral → Buy
2024-07-22 開始されました Needham Buy
2024-04-29 アップグレード Morgan Stanley Equal-Weight → Overweight
2024-03-19 開始されました Robert W. Baird Outperform
2024-02-06 開始されました UBS Buy
2024-01-25 開始されました RBC Capital Mkts Outperform
2023-12-13 開始されました Citigroup Buy
2023-08-08 アップグレード BofA Securities Underperform → Neutral
2023-01-05 開始されました Piper Sandler Neutral
2022-11-01 開始されました Loop Capital Buy
2022-09-07 再開されました Mizuho Buy
2021-08-10 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-06-10 開始されました Berenberg Buy
2021-01-08 開始されました Jefferies Buy
2020-12-16 開始されました Mizuho Buy
2020-09-29 開始されました BofA Securities Underperform
2020-09-10 開始されました Morgan Stanley Overweight
2020-04-28 繰り返されました H.C. Wainwright Buy
2020-04-14 開始されました Cowen Outperform
2019-12-30 繰り返されました H.C. Wainwright Buy
2019-12-17 繰り返されました H.C. Wainwright Buy
2019-12-16 繰り返されました Guggenheim Buy
2019-10-16 開始されました Guggenheim Buy
2019-09-18 開始されました William Blair Outperform
2019-05-28 開始されました SunTrust Buy
2019-05-23 繰り返されました H.C. Wainwright Buy
2019-04-08 開始されました SVB Leerink Outperform
2019-03-15 繰り返されました H.C. Wainwright Buy
2016-10-03 再開されました Brean Capital Buy
2015-12-15 開始されました Cantor Fitzgerald Buy
2015-12-14 開始されました Ladenburg Thalmann Buy
すべてを表示

Axsome Therapeutics Inc (AXSM) 最新ニュース

pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) General Counsel Hunter R. Murdock Sells 7,500 Shares - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome therapeutics’ general counsel sells $2.28 million in stock - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven? - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Axsome Therapeutics to Present SYMBRAVO® Clinical Data at the 67th Annual Scientific Meeting of the American Headache Society - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

Prosperity Wealth Management Inc. Buys New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 18, 2025
pulisher
Jun 18, 2025

SYMBRAVO Breakthrough: New Data Reveals Effectiveness in CGRP-Resistant Migraine Patients - Stock Titan

Jun 18, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $172.33 Average Target Price from Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics (AXSM) Supports Migraine Awareness and Commu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - The Manila Times

Jun 16, 2025
pulisher
Jun 16, 2025

Axsome Therapeutics Partners With Migraine Association to Help 40 Million US Patients Find Better Days - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Purchases 21,986 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Q3 EPS Forecast for Axsome Therapeutics Decreased by Analyst - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Royal Bank of Canada Has Lowered Expectations for Axsome Therapeutics (NASDAQ:AXSM) Stock Price - MarketBeat

Jun 15, 2025
pulisher
Jun 15, 2025

Axsome initiated with an Outperform at Oppenheimer on revenue boost - MSN

Jun 15, 2025
pulisher
Jun 15, 2025

Rhumbline Advisers Increases Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 15, 2025
pulisher
Jun 14, 2025

Axsome fell after FDA refuses to review AXS-14 application - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Equities Analysts Issue Forecasts for AXSM FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market By Investing.com - Investing.com Nigeria

Jun 14, 2025
pulisher
Jun 14, 2025

Axsome Therapeutics’ SWOT analysis: stock’s potential in CNS market - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

Assenagon Asset Management S.A. Purchases 623,717 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Mark L. Jacobson Sells 25,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 13, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Pallas Capital Advisors LLC - MarketBeat

Jun 13, 2025
pulisher
Jun 12, 2025

Needham & Company LLC Cuts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $150.00 - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Capital Adjusts Price Target for AXSM, Maintains Outperform Rating | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Axsome Therapeutics (AXSM) Target Price Adjusted by RBC Capital | AXSM Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

RBC Lowers Price Target on Axsome Therapeutics to $186 From $193, Keeps Outperform Rating - MarketScreener

Jun 12, 2025
pulisher
Jun 11, 2025

Axsome Presents Positive Phase 3 Data for AXS-12 in Narcolepsy at SLEEP 2025 - HCPLive

Jun 11, 2025
pulisher
Jun 11, 2025

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OSCR, AXSM and ET - ACCESS Newswire

Jun 11, 2025
pulisher
Jun 11, 2025

13 Biotech Stocks with Huge Upside Potential - Insider Monkey

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Therapeutics Highlights Seven Presentations on AXS-12 and Solriamfetol at SLEEP 2025 Conference - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Axsome Unveils Phase 3 Narcolepsy Trial Results Among 7 Major Presentations at SLEEP 2025 - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Axsome Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 02 - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc. Announces Availability of Symbravo (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine with or Without Aura in Adults - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - simplywall.st

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics Launches SYMBRAVO for Migraine Relief - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $185 From $190, Maintains Buy Rating - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (AXSM) Launches SYMBRAVO for Migraine Relief in the U.S. | AXSM Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Revolutionary Migraine Drug SYMBRAVO Now Available: Fast-Acting Relief Targets Multiple Pain Pathways - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics (NASDAQ:AXSM) Given New $150.00 Price Target at Needham & Company LLC - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Axsome Therapeutics at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Canada

Jun 10, 2025
pulisher
Jun 09, 2025

Axsome’s fibromyalgia drug application hits FDA roadblock By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Axsome Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:AXSM - Benzinga

Jun 09, 2025

Axsome Therapeutics Inc (AXSM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Axsome Therapeutics Inc (AXSM) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Murdock Hunter R.
General Counsel
Jun 23 '25
Option Exercise
29.91
6,014
179,879
6,014
Murdock Hunter R.
General Counsel
Jun 20 '25
Sale
102.47
7,500
768,525
0
Murdock Hunter R.
General Counsel
Jun 23 '25
Sale
100.12
6,014
602,122
0
$21.01
price up icon 1.80%
$35.71
price down icon 0.18%
$22.83
price up icon 0.62%
$96.88
price down icon 0.67%
$111.47
price up icon 0.91%
biotechnology ONC
$243.50
price up icon 0.85%
大文字化:     |  ボリューム (24 時間):